Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > the protocol change notice from Health Canada
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(943)
•••
Comment by wildbird1on Oct 29, 2023 8:13am
259 Views
Post# 35706149

RE:RE:the protocol change notice from Health Canada

RE:RE:the protocol change notice from Health Canada
Legit62 wrote: My thought on this is that this shouldnt affect our BTD or AA timing, since we already have the patients needed for that and they were just going to resubmit another pre BTD approval, Correct??? Im still optimistic for late 4TH q 23 or 1ST q 24 with possible JV news soon after that


Legit62...You are correct this new protocol will not affect the pre-BTD & BTD application.

For now this new protocol has only been approved for Canadian patients. In order for this new protocol to apply to US patients TLT would have to first receive a letter of approval from the FDA Institutional Review Board(IRB) (Google it).

For now the pre-BTD & BTD application follow its normal course.

Note:
In the Oct 16,2023 Pressrelease R.Dumoulin(TLT CEO) said " Theralase is investigating potential partnership for commercialization financing and distribution of this ACT technology on an international basis."
It is the first time that TLT is using a word(investigating) that indicate that Dr Lbiati has seriously started to look for a partner.
Needless to say that the deal will be conditional to the FDA approval of TLT- Ruvidar.




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities